Avalon GloboCare Corp (NASDAQ:ALBT) shares rose in early trade after it announced a partnership with medical device company Qi Diagnostics to co-develop international multi-center clinical studies for the DKAir breathalyzer device for the early detection of diabetic ketoacidosis (DKA).
Developed by Qi Diagnostics, the DKAir is a handheld breathalyzer that allows diabetic patients to detect the level of acetone in their breath.
Avalon said that the device provides a non-invasive, rapid, convenient, low-cost tool for the early detection of DKA, a serious complication of diabetes that can be potentially life-threatening if untreated.
Preclinical research has been completed and clinical studies for DKAir are expected to commence in the first quarter of 2024, it said.
“DKAir allows for early detection of this dreadful complication so appropriate medical care may be sought,” Avalon CEO Dr. David Jin said in a statement.
“Sometimes DKA can also be the first sign of diabetes in people who haven’t yet been diagnosed. Additionally, DKA can be precipitated by other illnesses in diabetic patients.”
Investors welcomed the news, with Avalon’s shares adding 22.6% at US$0.92 in the early afternoon on Wednesday.
Avalon is a commercial-stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services.
- Updated with share price movement -
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on X, formerly known as Twitter, @emilyjjarvie